Smeeth, L; Thomas, S; Vallance, P; (2005) Vascular events after acute infection or vaccination - Reply. The New England journal of medicine, 352 (11). p. 1152. ISSN 0028-4793
https://researchonline.lshtm.ac.uk/id/eprint/13811

Downloaded from: http://researchonline.lshtm.ac.uk/13811/

DOI:

Usage Guidelines:

Please refer to usage guidelines at https://researchonline.lshtm.ac.uk/policies.html or alternatively contact researchonline@lshtm.ac.uk.

Available under license: Copyright the publishers
scribed in this manner should be counseled about the risks and clinical presentation of these and other potential drug interactions.

Ann K. Wittkowsky, Pharm.D.
University of Washington School of Pharmacy
Seattle, WA 98195
akwitt@u.washington.edu


THE AUTHORS REPLY: Drs. Grönefeld and Hohnloser request information on antithrombotic treatment. In our study protocol, anticoagulation was not standardized but was left to the local practice of each center. Fifteen patients (7 percent) were treated with warfarin, and 38 (18 percent) with aspirin. During the follow-up period, no patient had a transient ischemic attack, stroke, or arterial embolism. However, we believe that the indications for antithrombotic therapy are not clearly defined in patients with transient, symptomatic episodes of atrial fibrillation that are treated with either the pill-in-the-pocket approach or long-term oral prophylaxis; this point deserves further investigation.

Drs. Konety and Olshansky underscore the lack of a control group. In many studies carried out in hospitalized patients, oral flecainide or propafenone has been shown to be superior to placebo in rapidly terminating atrial fibrillation of recent onset. In our opinion, further study to demonstrate this superiority was not indicated. We agree with Drs. Konety and Olshansky that the pill-in-the-pocket approach or long-term oral prophylaxis; this point deserves further investigation.

Drs. Konety and Olshansky underscore the lack of a control group. In many studies carried out in hospitalized patients, oral flecainide or propafenone has been shown to be superior to placebo in rapidly terminating atrial fibrillation of recent onset. In our opinion, further study to demonstrate this superiority was not indicated. We agree with Drs. Konety and Olshansky that the pill-in-the-pocket approach or long-term oral prophylaxis; this point deserves further investigation.

Nicola Baldi, M.D.
Ospedale SS. Annunziata
44042 Cento, Italy
p.alboni@ausl.fe.it

Giovanni I. Botto, M.D.
Ospedale S. Anna
22100 Como, Italy

Vascular Events after Acute Infection or Vaccination

TO THE EDITOR: In their article about cardiovascular events after acute infections (Dec. 16 issue), Smeeth et al. do not discuss alternative, time-honored explanations for the occurrence of cardiovascular events within three days after acute infections. A reasonable explanation could be that fever...

and the accompanying tachycardia trigger such events, not to mention the procoagulant effects an acute infection can have. The hypoxemia that accompanies a respiratory (but not urinary) infection can adversely affect vulnerable tissue, not to mention have procoagulant effects. A less common phenomenon is a myocardial infarction masquerading as a respiratory infection. In one recent study, more than 40 percent of cases of myocardial infarction in women had the appearance of a respiratory infection. The widely held view about the role that inflammation plays in atherosclerosis and cardiovascular events has prevented recognition and discussion of the apparent paradox that common anti-inflammatory agents, such as corticosteroids and nonsteroidal antiinflammatory drugs (with the exception of aspirin), may actually increase, rather than decrease, adverse cardiovascular outcomes. 

Michael Bursztyn, M.D.
Hadassah University Hospital, Mount Scopus
Jerusalem 91240, Israel
bursz@cc.huji.ac.il


TO THE EDITOR: Smeeth et al. found that persons with acute infections have an increased risk of cardiovascular and cerebrovascular events, whereas those who have been vaccinated do not. They conclude that this “lends strong support to the concept that systemic inflammation itself alters the probability of the occurrence of a vascular event.” We believe that this conclusion based on their data is flawed. Not discussed is the influence of acute infection on stress and on demand-induced ischemia. Acute infections, particularly those of the respiratory tract, may be associated with hemodynamic stresses that are not typically induced by vaccination. These hemodynamic stresses in high-risk older persons, such as those in the study by Smeeth et al., who had an increased prevalence of coronary artery disease, may account for the increased rates of myocardial events noted in the study. Although evidence for a link between inflammation and vascular events is abundant, demand-induced ischemia due to acute hemodynamic stressors of a clinically significant degree may be a more straightforward explanation of the findings of this study.

Nima Sharifi, M.D.
National Institutes of Health
Bethesda, MD 20892

Pirooz S. Mofrad, M.D.
Georgetown University Hospital
Washington, DC 20010

THE AUTHORS REPLY: Bursztyn raises the question of whether there might have been cases of misdiagnosis of myocardial infarction as respiratory infection. We did consider this important point. Our study identified an increase in the risk of myocardial infarction or stroke after a case of urinary tract infection or respiratory infection. We think it unlikely that myocardial infection was misdiagnosed as urinary tract infection or that either urinary tract infection or respiratory tract infection was misdiagnosed as stroke. Therefore, our conclusions that two different infectious processes increase the rate of cardiovascular events seem secure. As for the interesting question about associations between anti-inflammatory drugs and event rates, it is unfortunate that the interpretation of the data are difficult because of confounding and the diversity of underlying disease states. Although we recognize that some drugs have detrimental effects, we are less certain than Dr. Bursztyn that, as a group, drugs that reduce inflammation are necessarily harmful in terms of cardiovascular events.

In our article, we list several possible mechanisms that might explain the association between acute infection and a short-term increase in cardiovascular risk. Drs. Sharifi and Mofrad suggest an additional one: that hemodynamic stresses may have played a part in mediating the effect. We agree with the correspondents that infection and systemic inflammation increase the heart rate and can alter hemodynamics and myocardial oxygen demand. Although it is conceivable that these acute changes may have contributed to the effect we observed, it seems less likely that they would have persisted dur-
Altered Nuclear Transfer

TO THE EDITOR: Altered nuclear transfer is a procedure that has been proposed as a morally acceptable means of procuring human embryonic stem cells. In their Perspective article, Melton et al. (Dec. 30 issue) appear to misunderstand, and therefore prematurely dismiss, the promising possibilities of this proposal.

The proposal for altered nuclear transfer, which was developed in wide consultation with leading scientists, moral philosophers, and religious authorities, represents a “third option” — a technological solution to the current moral impasse regarding the destruction of human embryos to obtain embryonic stem cells.

Using the techniques of somatic-cell nuclear transfer, but with the intentional alteration of the nucleus before transplantation, we could construct a biologic entity that, from its very inception, lacked the attributes and capacities of a human embryo. Studies with mice already provide evidence that we may be able to generate functional embryonic stem cells from a system that is not an organism but is biologically (and morally) more akin to tissue or cell culture. There is a natural precedent for entities that lack the characteristics of organisms, yet are capable of generating embryonic stem cells or their functional equivalent. Teratomas are germ-cell tumors that generate all three primary embryonic germ-layer cell types, as well as more advanced cells and tissues. Yet these chaotic, disorganized, and nonfunctional masses entirely lack the structural and dynamic character of an organism.

Most of the objections raised by Melton et al. are based on a mistaken identification of altered nuclear transfer with silencing of the gene CDX2, but — as was clearly stated in my presentation to the President’s Council on Bioethics — there are many potential approaches involving the alteration of genes that are necessary for early intercellular signaling, cell differentiation, or integrated patterning of development. The exact gene or combination of genes will depend on the level of disorganization deemed essential to fulfill the moral criteria of this project.

Many Americans believe that a decent society should not build the foundations of its biomedical science on the intentional creation and destruction of human embryos. Such a view is consistent with the enduring traditions of our profession, encoded in the Hippocratic oath and extended in the 1948 Declaration of Geneva, which explicitly states, “I will maintain the utmost respect for human life, from the time of conception.” Altered nuclear transfer is not a “distraction” or a “diversion of resources” as stated by Melton et al., but a morally reasonable and technologically feasible proposal that honors the important human goods being defended by both sides of this difficult debate.

William B. Hurlbut, M.D.
Stanford University
Stanford, CA 94305


THE AUTHORS REPLY: We did not misunderstand Hurlbut’s proposal. We focused on CDX2 because this is the example that Hurlbut offered, but our point was more general. To repeat: “We see no basis for concluding that the action of CDX2 (or indeed any other gene) represents a transition point at which a human embryo acquires moral status.”

Hurlbut now acknowledges that “the exact gene or combination of genes will depend on the level of